Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 30, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity and capital structure updates.
- Shares Repurchased: 2,500,000 Ordinary shares.
- Repurchase Price: 1,282.87 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.13% of total voting rights).
- Shares in Issue: 5,521,203,804 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the November 30, 2007 transaction. The total number of shares in issue remains 5,521,203,804, which serves as the denominator for shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,521,203,804) for calculating disclosure thresholds.
- Confirm the updated Treasury share count (504,194,158) and its percentage of voting rights (9.13%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for full financial results.